Acceleron Pharma (XLRN) Misses Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Misses Q3 EPS by 1c

Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results

November 7, 2017 7:00 AM EST

-Presented vision and strategic focus in hematological, neuromuscular, and pulmonary diseases at September R&D Day-

-Obtained the rights to fund, develop, and lead global commercialization of sotatercept in pulmonary arterial hypertension; robust preclinical results show potential for first-in-class disease modifying approach-

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30,... More